AstraZeneca Exanta Risk Management Plan May Not Prevent Liver Injury, FDA Says
This article was originally published in The Pink Sheet Daily
Cardiovascular & Renal Drugs Advisory Committee should determine whether AstraZeneca's proposed risk management plan for Exanta addresses delayed toxicity after short-term treatment. FDA also raises concerns about aspects of Exanta's clinical trial design.
You may also be interested in...
The company is also seeking an indication for longer term secondary prevention of venous thromboembolism. Phase III results show oral direct thrombin inhibitor is equal to or better than warfarin, without dose adjustment.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states